Core Viewpoint - The announcement from 加科思-B indicates a strategic partnership and investment that could enhance its position in the cardiovascular drug development sector [1] Group 1: Investment and Financial Details - 加科思-B's subsidiary, 北京加科思, and 加科瑞康 have signed an investment agreement with a partner, involving a cash payment of RMB 125 million as an initial payment and RMB 75 million as a milestone payment for acquiring 80% of 加科瑞康 [1] - Following the completion of the transaction, 北京加科思 will hold 10% of 加科瑞康, 海松资本 will own 80%, and the industry partner will have 10% [1] Group 2: Business Focus - 加科瑞康 specializes in the internal research and development of cardiovascular disease treatment drugs and holds intellectual property related to early-stage cardiovascular research and development projects [1]
加科思-B高开近3% 附属北京加科思拟转让加科瑞康股权